ANTIVIRAL EFFECT OF PROLONGED INTERMITTENT LYMPHOBLASTOID ALPHA INTERFERON TREATMENT IN CHRONIC HEPATITIS-B
ANTIVIRAL EFFECT OF PROLONGED INTERMITTENT LYMPHOBLASTOID ALPHA INTERFERON TREATMENT IN CHRONIC HEPATITIS-B
复制标题
DOI：
10.1136/gut.33.8.1094
复制
发表时间：
1992-08-01
期刊：
影响因子：
24.5
通讯作者：
MULDER, CJJ
中科院分区：
文献类型：
--
作者：
JANSSEN, HLA;BERK, L;MULDER, CJJ
在一项欧洲多中心研究中，40名HBeAg阳性慢性B型肝炎病毒（HBV）感染的患者按照以下方案每天用5百万单位的淋巴母细胞α-干扰素治疗：4周的初始疗程，4周的休息和持续16至30周的第二疗程。随访52周后，22例患者（55%）出现应答（HBeAg血清转换和HBV-DNA阴性）。HBsAg血清转换发生在5例（12.5%）。1例患者在停止治疗后血清HBeAg和HBV-DNA复发。根据缓解预测模型，观察到的缓解率与可能出现缓解的患者的选择无关。初始干扰素疗程诱导血清HBV-DNA和HBeAg水平分别降低87%和18%，导致第二个长期疗程开始时病毒复制活性水平显著低于基线水平。随访24周（第二疗程第16周），19例（48%）患者出现应答，13例（32%）患者出现部分应答（HBeAg
In a European multicentre study 40 patients with HBeAg positive chronic hepatitis B virus (HBV) infection were treated with 5 mega units of lymphoblastoid alpha-interferon daily according to the following regimen: a four week primer course, four weeks of rest and a second course lasting 16 to 30 weeks. After 52 weeks of follow up, a response (HBeAg seroconversion and HBV-DNA negativity) was observed in 22 patients (55%). HBsAg seroconversion occurred in five patients (12.5%). One patient exhibited a relapse for serum HBeAg and HBV-DNA after cessation of treatment. According to a response prediction model, the observed response rate was not related to the selection of patients likely to respond. The initial interferon course induced a reduction of the serum HBV-DNA and HBeAg levels of 87% and 18%, respectively, leading to a significantly lower level of viral replication activity at the start of the second longterm course compared with baseline. After 24 weeks of follow up (week 16 of the second course), 19 (48%) patients exhibited a response, 13 (32%) a partial response (HBeAg